Abstracts tagged "safety and sleep"

Abstract Number: 1974 • ACR/ARHP Annual Meeting 2017
Efficacy and Safety of Pregabalin for Fibromyalgia in a Population of Chinese Patients: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Xiao Zhang¹, Huji Xu², Zhiyi Zhang³, Yang Li⁴, Lynne Pauer⁵, Shanmei Liao⁶, Gaiping Xu⁷ and Fengchun Zhang⁸, ¹Guangdong General Hospital, Guangdong, China, Guangdong, China, ²Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, ³The First Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁴The Second Affiliated Hospital of Harbin Medical University, Harbin, China, Harbin, China, ⁵Pfizer, Groton, CT, USA, Groton, CT, ⁶Pfizer (China) Statistics Department, Global Innovative Pharma Business, Shanghai, China, Shanghai, China, ⁷Pfizer (China) Clinical Development, Global Innovative Pharma Business, Beijing, China, Beijing, China, ⁸Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Global trial data demonstrate the efficacy of pregabalin for the treatment of pain associated with fibromyalgia (FM), but there are currently no approved medical…
Abstract Number: 52 • ACR/ARHP Annual Meeting 2016
Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Andrew Clair¹, Ed Whalen¹, Neal Thomas¹ and Lynne Pauer², ¹Pfizer, New York, NY, ²Pfizer, Groton, CT
Background/Purpose: Pregabalin is often administered for treatment of fibromyalgia (FM) at daily doses lower than approved by the US Food and Drug Administration (starting dose…